Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $9.47 per share which beat the analyst consensus estimate of $8.89 by 6.52 percent. This is a 15.21 percent increase over earnings of $8.22 per share from the same period last year. The company reported quarterly sales of $3.605 billion which beat the analyst consensus estimate of $3.483 billion by 3.51 percent. This is a 19.02 percent increase over sales of $3.029 billion the same period last year.